AU2020394597B2 - 1,2,4-oxadiazole derivatives as liver X receptor agonists - Google Patents
1,2,4-oxadiazole derivatives as liver X receptor agonists Download PDFInfo
- Publication number
- AU2020394597B2 AU2020394597B2 AU2020394597A AU2020394597A AU2020394597B2 AU 2020394597 B2 AU2020394597 B2 AU 2020394597B2 AU 2020394597 A AU2020394597 A AU 2020394597A AU 2020394597 A AU2020394597 A AU 2020394597A AU 2020394597 B2 AU2020394597 B2 AU 2020394597B2
- Authority
- AU
- Australia
- Prior art keywords
- phenyl
- methyl
- oxadiazol
- trifluoromethyl
- phenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940061P | 2019-11-25 | 2019-11-25 | |
| US62/940,061 | 2019-11-25 | ||
| US202063106293P | 2020-10-27 | 2020-10-27 | |
| US63/106,293 | 2020-10-27 | ||
| PCT/IB2020/061053 WO2021105857A1 (en) | 2019-11-25 | 2020-11-23 | 1,2,4-oxadiazole derivatives as liver x receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020394597A1 AU2020394597A1 (en) | 2022-06-02 |
| AU2020394597B2 true AU2020394597B2 (en) | 2024-03-14 |
Family
ID=73654860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020394597A Expired - Fee Related AU2020394597B2 (en) | 2019-11-25 | 2020-11-23 | 1,2,4-oxadiazole derivatives as liver X receptor agonists |
Country Status (22)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022243907A1 (en) * | 2021-05-20 | 2022-11-24 | Novartis Ag | Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione |
| WO2022249006A1 (en) * | 2021-05-24 | 2022-12-01 | Novartis Ag | Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists |
| KR102882404B1 (ko) | 2022-10-28 | 2025-11-06 | (주)케이메디켐 | 신규 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015187840A2 (en) * | 2014-06-03 | 2015-12-10 | Duke University | Methods and formulations for treatment of ocular disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201120016A (en) | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
| EP2753608A1 (en) * | 2011-09-08 | 2014-07-16 | Allergan, Inc. | 3-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1 phosphate receptors modulators |
| WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| WO2020123869A1 (en) | 2018-12-13 | 2020-06-18 | eyeNOS, Inc. | Lxr agonist in topical ophthalmic formulation for treatment of dry-eye disorder |
-
2020
- 2020-11-20 PY PY202002077235A patent/PY2077235A/es unknown
- 2020-11-20 UY UY0001038964A patent/UY38964A/es not_active Application Discontinuation
- 2020-11-23 MX MX2022006151A patent/MX2022006151A/es unknown
- 2020-11-23 CR CR20220227A patent/CR20220227A/es unknown
- 2020-11-23 TW TW109140930A patent/TW202132289A/zh unknown
- 2020-11-23 CA CA3157657A patent/CA3157657A1/en active Pending
- 2020-11-23 IL IL291958A patent/IL291958A/en unknown
- 2020-11-23 AU AU2020394597A patent/AU2020394597B2/en not_active Expired - Fee Related
- 2020-11-23 JP JP2022529931A patent/JP2023503320A/ja active Pending
- 2020-11-23 PH PH1/2022/551248A patent/PH12022551248A1/en unknown
- 2020-11-23 US US17/101,510 patent/US11427586B2/en active Active
- 2020-11-23 KR KR1020227020461A patent/KR20220106778A/ko not_active Ceased
- 2020-11-23 EP EP20817082.9A patent/EP4065228A1/en not_active Withdrawn
- 2020-11-23 WO PCT/IB2020/061053 patent/WO2021105857A1/en not_active Ceased
- 2020-11-23 BR BR112022009942A patent/BR112022009942A2/pt not_active Application Discontinuation
- 2020-11-23 CN CN202080081467.7A patent/CN114746149A/zh active Pending
- 2020-11-23 PE PE2022000828A patent/PE20221785A1/es unknown
-
2022
- 2022-05-19 CO CONC2022/0006645A patent/CO2022006645A2/es unknown
- 2022-05-19 EC ECSENADI202240362A patent/ECSP22040362A/es unknown
- 2022-05-19 CL CL2022001323A patent/CL2022001323A1/es unknown
- 2022-05-20 DO DO2022000107A patent/DOP2022000107A/es unknown
- 2022-05-23 JO JOP/2022/0124A patent/JOP20220124A1/ar unknown
- 2022-06-06 US US17/805,487 patent/US20220340573A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015187840A2 (en) * | 2014-06-03 | 2015-12-10 | Duke University | Methods and formulations for treatment of ocular disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023503320A (ja) | 2023-01-27 |
| US20220340573A1 (en) | 2022-10-27 |
| IL291958A (en) | 2022-06-01 |
| PH12022551248A1 (en) | 2023-09-11 |
| ECSP22040362A (es) | 2022-06-30 |
| MX2022006151A (es) | 2022-08-02 |
| EP4065228A1 (en) | 2022-10-05 |
| TW202132289A (zh) | 2021-09-01 |
| CN114746149A (zh) | 2022-07-12 |
| CA3157657A1 (en) | 2021-06-03 |
| CR20220227A (es) | 2022-06-15 |
| KR20220106778A (ko) | 2022-07-29 |
| BR112022009942A2 (pt) | 2022-08-09 |
| DOP2022000107A (es) | 2022-06-15 |
| UY38964A (es) | 2021-06-30 |
| CO2022006645A2 (es) | 2022-05-31 |
| JOP20220124A1 (ar) | 2022-05-23 |
| WO2021105857A1 (en) | 2021-06-03 |
| CL2022001323A1 (es) | 2023-03-24 |
| US20220064164A1 (en) | 2022-03-03 |
| AU2020394597A1 (en) | 2022-06-02 |
| PE20221785A1 (es) | 2022-11-22 |
| PY2077235A (es) | 2022-10-31 |
| US11427586B2 (en) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021047622A1 (zh) | 吡啶氮氧化合物及其制备方法和用途 | |
| US20220340573A1 (en) | 1,2,4-oxadiazole derivatives as liver x receptor agonists | |
| US20240043403A1 (en) | Heteroaryl carboxamide compound | |
| JP2007536369A (ja) | プロリン及びモルホリン誘導体の新規化合物 | |
| US12435040B2 (en) | 1,3-substituted cyclobutyl derivatives and uses thereof | |
| AU2024275602A1 (en) | Sulfonamide compound, preparation method therefor, and pharmaceutical use thereof | |
| JP2019532077A (ja) | 治療用化合物及びその使用方法 | |
| EP4702026A1 (en) | Tricyclic fused imidazole compounds as cd38 modulators and uses thereof | |
| RU2730520C2 (ru) | Твердые формы альфа, омега дизамещенного дигидроксициклопентильного соединения и способы их получения и применения | |
| EA009589B1 (ru) | Производные морфолина для применения в качестве агонистов допамина при лечении половой дисфункции | |
| US20230002366A1 (en) | Indene derivatives useful in treating pain and inflammation | |
| CN119118894A (zh) | Trpv4受体配体 | |
| CA2995161A1 (en) | 2,3,4,5-tetrahydropyridin-6-amine derivatives | |
| WO2018149991A1 (fr) | Dérivés sulfonamides hydroxylés en tant qu'agonistes inverses du récepteur gamma orphelin associé aux rétinoïdes ror gamma (t) | |
| WO2022249006A1 (en) | Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists | |
| BR122025005591A2 (pt) | Uso de e processo para preparação de derivados de ciclobutila 1,3-substituída, combinação farmacêutica, e kit | |
| BR122025005591B1 (pt) | Uso de e processo para preparação de derivados de ciclobutila 1,3- substituída, combinação farmacêutica, e kit | |
| JP2022505401A (ja) | ムスカリンm1受容体陽性アロステリックモジュレーターとしてのピロロ-ピリダジン誘導体 | |
| BR112023019496B1 (pt) | Derivados de ciclobutila 1,3-substituída, e composição farmacêutica | |
| JP2009517483A (ja) | 一酸化窒素シンターゼの二量化の抑制剤としてのイミダゾール誘導体 | |
| EA050893B1 (ru) | Производные 1,3-замещенного циклобутила и способы их применения | |
| JP2025531367A (ja) | Trpv1アンタゴニストの結晶多形形態およびその製剤 | |
| JP2025537242A (ja) | 含窒素スピロ環式化合物、医薬組成物及びその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK25 | Application lapsed reg. 22.2i(2) - failure to pay acceptance fee |